89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks – Yahoo Finance

by

  1. 89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks Yahoo Finance
  2. Chasing Akero, 89bio reduces scarring in midphase NASH trial to hit primary goals, tee up phase 3 FierceBiotech
  3. ETNB Stock Rockets As It Takes On Akero In Fatty Liver Disease Investor’s Business Daily
  4. ETNB stock jumps on topline data for NASH candidate (NASDAQ:ETNB) Seeking Alpha
  5. 89bio’s stock rallies 48% on new NASH data MarketWatch
  6. View Full Coverage on Google News

Read original article here

Leave a Comment